“GHK-Cu (the 'glow peptide') suppresses 74% of 54 genes driving aggressive metastatic cancer" / "GHK-Cu suppresses 74% of 54 genes driving aggressive metastatic cancer... a molecule your body naturally produces, with the demonstrated capacity to shift gene expression away from malignancy at a systemic level.”
Plain restatementA 2010 study reported that the tripeptide GHK, queried against a gene-expression database, was associated with reversal of the expression pattern of a 54-gene prognostic signature derived from early-stage colorectal cancer patients who later developed metastasis.
This claim comes from a real 2010 study, but the number and the meaning are both wrong. The study analyzed tissue from 82 people and built a 54-gene pattern that helped predict which early-stage colorectal cancer patients would later develop metastasis. Researchers then ran that pattern through a computer database of how cancer cells in petri dishes respond to over 1,300 chemicals, and the peptide GHK came up as one of two compounds whose expression fingerprint ran opposite to the cancer pattern. The figure reported was 70 percent, not 74 percent. The number 74 in the study refers to microarray probe sets, not a percentage. Critically, nobody gave GHK-Cu to a person or an animal with colon cancer in this research, the 54 genes were prediction markers rather than proven drivers of cancer, and much of the popular writeup of this finding comes from the peptide's discoverer, who founded copper peptide companies and holds related patents. GHK-Cu remains an interesting molecule with genuine skin research behind it, but there is no human trial evidence that it treats or prevents cancer.
[drifted from the evidence:] GHK-Cu (the [drifted from the evidence:] 'glow peptide') suppresses 74% of 54 genes driving aggressive metastatic cancer" / "GHK-Cu suppresses 74% of 54 genes driving aggressive metastatic cancer... a [drifted from the evidence:] molecule your body naturally produces, with the [drifted from the evidence:] demonstrated capacity to shift gene expression [drifted from the evidence:] away from malignancy at a [drifted from the evidence:] systemic level.
[added by the neutral restatement:] A 2010 study reported that the [added by the neutral restatement:] tripeptide GHK, queried against a [added by the neutral restatement:] gene-expression database, was associated with [added by the neutral restatement:] reversal of the expression [added by the neutral restatement:] pattern of a [added by the neutral restatement:] 54-gene prognostic signature derived from early-stage colorectal cancer patients who later developed metastasis.
Red-tinted words in the claim drifted from the evidence. Green-tinted words are what a neutral restatement needs.
The trace / claim to source
- A real, peer-reviewed 2010 paper exists in *Clinical & Experimental Metastasis*.
- It really did identify a 54-gene set from colorectal cancer patients.
- It really did report that GHK and securinine emerged from a Connectivity Map query as compounds that reverse that signature's differential expression.
- The database search produced only two substances able to down-regulate expression of the metastatic genes, and GHK produced the result at a low non-toxic 1 micromolar concentration while securinine required 18 micromolar.
- GHK is genuinely a naturally occurring human plasma peptide that declines with age.
- The number 70 and the number 54 both appear in the real literature. ---
- **Numerical error.** The figure in every traceable source is **70%**, not 74%. The number 74 appears in the source as the count of microarray **probe sets** corresponding to the 54 genes. The post appears to have fused two different numbers into a percentage that no source states.
- **Ambiguity collapsed in the claim's favor.** The primary paper's own wording says cMap was queried with a subset (70%) of these genes , meaning 70% describes the portion of the gene set used to run the query. Pickart's reviews later reframed the same 70% as the proportion of genes suppressed. The post inherits the stronger secondary framing, then inflates the number further.
- **Unsupported causal inference.** The claim calls these "genes driving aggressive metastatic cancer." They were selected as a **prognostic classifier**, with modest performance: an estimated prediction accuracy of 71% and sensitivity of only 0.58 . Predictive markers are not demonstrated drivers.
- **In silico presented as biological demonstration.** "Suppresses" implies a measured effect on cancer. What happened was a computational match against expression fingerprints from cultured cell lines. The original authors framed it as a hypothesis, saying only that it suggests they have combinatorial therapeutic effect on the metastasis-prone patients.
- **Species and system extrapolation.** Cell line transcriptomics are being presented as human clinical outcomes.
- **Scope inflation.** "Aggressive metastatic cancer" in general. The study was specifically early-stage, mismatch-repair-proficient, sporadic colorectal cancer. One cancer type, one patient subgroup.
- **"Systemic level" overreach.** Nothing in this evidence base concerns systemic administration in humans. cMap exposure was direct application to cells in a dish at 1 micromolar.
- **Compound substitution.** The claim says GHK-Cu. The database entry is GHK.
- **Authority framing.** The post positions itself as "the science, not the sales pitch," but the amplification chain runs largely through review articles authored by the peptide's commercial patent holder. ---
- Whether Hong et al.'s "70%" means "70% of genes were reversed" or "the query used 70% of the gene set" cannot be fully resolved from the abstract alone. Full-text access was not obtained. Either reading refutes 74%.
- Whether any registered human clinical trial of GHK or GHK-Cu for cancer treatment or prevention exists could not be confirmed within search limits. No such trial surfaced in searching. This is an absence of found evidence, not proof of absence.
- The quality, replication status, and dosing of the 1980s-era mouse sarcoma work cited by Pickart were not independently verified beyond the review that reports it.
- The exact identity and copper-complexation state of the cMap "Gly-His-Lys" instance was not verified from Broad Institute records directly. ---
The claim traces to a single 2010 paper. Its purpose was prognostic, not therapeutic. The authors aimed to find a metastasis-prone signature for early stage mismatch-repair proficient sporadic colorectal cancer patients for better prognosis and informed use of adjuvant chemotherapy, analyzing genome-wide expression profiles of 82 age-, ethnicity- and tissue-matched patients and healthy controls using the Affymetrix U133 Plus 2 array. The best classification model yielded a 54 gene-set (74 probe sets) with an estimated prediction accuracy of 71%. The specificity, sensitivity, negative and positive predictive values of the signature are 0.88, 0.58, 0.84 and 0.65 respectively. The GHK finding is one sentence at the end of that paper: querying the Connectivity Map with a subset (70%) of these genes shows that Gly-His-Lys and securinine could reverse the differential expressions of these genes significantly, suggesting that they have combinatorial therapeutic effect on the metastasis-prone patients. Pickart's later review articles restate this as a suppression percentage: GHK suppressed RNA production in 70% of 54 human genes overexpressed in patients with an aggressive metastatic form of colon cancer and was active at a low nontoxic 1 micromolar concentration. In 2010, Hong et al. used Broad Institute's Connectivity Map to find molecules that could inhibit metastatic colon cancer. The Connectivity Map contains expression profiles that were evaluated in five cancer cell lines, in response to 1,309 bioactive small molecules. **No source anywhere states 74%.** The number 74 in this literature refers to probe sets, not a percentage. --- ## METHODOLOGY AND CONTEXT **Study design:** Retrospective microarray profiling of 82 matched patients and controls, followed by an in silico database query. This is a bioinformatics signature-matching exercise, not an experiment in which GHK-Cu was given to anything with cancer. **What the Connectivity Map actually is:** a reference database of gene expression changes in cultured cancer cell lines exposed to compounds. The original CMap was built primarily in the breast cancer epithelial cell line MCF7, with a subset of perturbagens also profiled in prostate cancer line PC3 and the nonepithelial lines HL60 (leukemia) and SKMEL5 (melanoma). A cMap "hit" means a compound's expression fingerprint runs statistically opposite to a query signature. It does not measure tumor shrinkage, survival, or metastasis. **The compound tested:** cMap profiled Gly-His-Lys, the bare tripeptide, in cell culture. The viral claim is about GHK-Cu, the copper complex sold in skincare and injectables. These are related but not identical, and no colon tissue or colon cancer patient was exposed to either in this work. **The 54 genes:** these were selected by a machine learning classifier for predictive accuracy, not established as causal drivers. The authors describe them as node molecules including YWHAB, MAP3K5, LMNA, APP, GNAQ, F3, NFATC2, and TGM2, which integrate multiple bio-functions in various compartments into an intricate molecular network, suggesting that cell-wide perturbations are involved in metastasis transformation. A prognostic classifier gene is a marker. It is not the same as a driver. **Conflict of interest:** the review literature amplifying this finding is dominated by one author with direct commercial interest. Pickart founded two companies to sell copper peptides, co-founding ProCyte, which he took to NASDAQ, and Skin Biology. He is also a named inventor on United States Patent 9,586,989, "Non-toxic skin cancer therapy with copper peptides." **Animal evidence:** limited and old. Pickart's own review cites a mouse sarcoma model in which a mixture of GHK-copper 2+ and ascorbic acid produced a 60% reduction in tumor growth. That is a single non-colorectal rodent experiment, not replicated at scale. ---
Complete reasoning
The reply receipt is formatted for pasting into the thread where the claim is circulating.
Compact share page: verify.trueseeker.com/s/e5070acc07bf/Ox38dFkUhGdwGDjoxwqVzEq
Ask this case
Answers come only from the case file above; nothing is added.
Does GHK-Cu actually suppress 74% of the genes linked to metastatic cancer?
No. The number 74% does not appear anywhere in the source literature. The real figure is 70%, and the number 74 actually refers to microarray probe sets, not a percentage.
Was GHK-Cu tested on cancer patients or animals with colon cancer?
No. The study was a computer database search comparing gene expression fingerprints from cultured cancer cell lines. Nobody gave GHK-Cu to a person or animal with colon cancer in this research.
Were the 54 genes proven to cause metastasis?
No. The 54 genes were selected by a machine learning classifier to help predict which patients might develop metastasis, with modest accuracy (71% prediction accuracy, 0.58 sensitivity). They were prognostic markers, not proven cancer drivers.
Is GHK-Cu the same compound that was actually tested in the study?
Not exactly. The study tested Gly-His-Lys, the bare tripeptide, in a cell-line database. The viral claim refers to GHK-Cu, the copper complex used in skincare, which is related but not identical to what was tested.
Who is promoting this claim, and do they have a financial interest?
Much of the popular writeup traces back to the peptide's discoverer, who founded two companies selling copper peptides and holds a related patent on copper peptide cancer therapy.